Intercept Pharm (ICPT) Posts Q2 Loss of 79c/Share; Issues Positive FLINT Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Intercept Pharm (ICPT) Posts Q2 Loss of 79c/Share; Issues Positive FLINT Data
August 12, 2014 9:07 AM EDT
BMO Capital analyst Jim Birchenough, M.D. reiterated an Outperform rating and $515 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following receipt of a draft manuscript for the FLINT OCA NASH trial authored by NIDDK.
Birchenough said, "We believe the results are better than expected with... More
August 12, 2014 9:03 AM EDT
Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating on Intercept Pharmaceuticals (NASDAQ: ICPT) and boosted his price target to $456.00 (from $323.00) ) following positive top-line FLINT data.
Somaiya commented, "The results greatly de-risk the regulatory process for OCA in NASH and could... More
August 12, 2014 8:18 AM EDT
Leerink Swann upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Market Perform to Outperform with a price target of $445.00 (from $270.00).
For an analyst ratings summary and ratings history on Intercept Pharmaceuticals click here. For more ratings news on Intercept Pharmaceuticals click here.
Shares of Intercept Pharmaceuticals closed at $237.18 yesterday.
...
More
August 11, 2014 4:00 PM EDT
Intercept Pharma (NASDAQ: ICPT) trading halted with news pending.
...
More
